Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies

Expert Opin Biol Ther. 2017 Sep;17(9):1053-1063. doi: 10.1080/14712598.2017.1346607. Epub 2017 Jul 10.


Alterations in the process of angiogenesis, either by excess or by defect, are present in different common pathologies. For this reason, great efforts are being made toward the development of pro- and anti-angiogenic therapies. Since endoglin levels are enhanced in tissues undergoing angiogenesis, and changes in its expression lead to alterations in vessel formation, endoglin has become an ideal target for these types of therapies. Areas covered: In this review, the role of endoglin in angiogenesis is summarized. In addition, the authors review pro- and anti-angiogenic therapies that are currently being used and new approaches that target endoglin. The article includes therapies that are both in preclinical and clinical development. Expert opinion: Endoglin is a very good target for anti-angiogenic therapy, as demonstrated by the positive results obtained with anti-endoglin antibodies. However, although endoglin in pro-angiogenic therapies has been successful in vitro, its use has not yet reached clinical settings. Moreover, the authors believe that establishing the exact role of endoglin in angiogenesis is essential and that this should be the next step in this field in the coming years.

Keywords: Angiogenesis; anti-angiogenic therapy; endoglin; endothelium; proangiogenic therapy.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Arteriovenous Malformations / pathology
  • Arteriovenous Malformations / therapy
  • Cell- and Tissue-Based Therapy
  • Endoglin / antagonists & inhibitors
  • Endoglin / metabolism*
  • Genetic Therapy
  • Humans
  • Immunotherapy
  • Neoplasms / blood supply
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Neovascularization, Pathologic
  • Signal Transduction / drug effects


  • Angiogenesis Inhibitors
  • Endoglin